Thevax Genetics Vaccine Co., Ltd.

Reber Genetics Co., Ltd.

Wei-I Chou

Hsiu-Kang Chang

Chia-Mao Wu

Jiun-Ming Wu

Chia-Jung Chang

Meng-Ju Tsai

Yan-Chiou Liao

Yu-Hsin Chien

Pao-Yen Lai

A recombinant baculovirus displaying on its envelop a fusion protein is disclosed. The fusion protein comprises a heterologous antigen, and a C-terminal region of baculovirus envelope GP64 protein, which has at least 100 amino acid residues in length and lacks a B12D5 binding epitope located within the central basic region of the GP64 protein. The genome of the recombinant baculovirus comprises a transgene encoding a fusion protein that comprises a signal peptide, the heterologous antigen, and the C-terminal region of the baculovirus envelope GP64 protein, in which the antigen is located between the signal peptide and the C-terminal region of the GP64 protein. Methods for eliciting an antigen-specific immunogenic response in a subject in need thereof are also disclosed.

Baculovirus display vectors and uses thereof

A fusion protein comprising an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, a translocation peptide, a fusion antigen, an endoplasmic reticulum retention sequence, and optionally a nuclear export signal is disclosed. The fusion antigen comprises a porcine reproductive and respiratory syndrome virus (PRRSV) ORF7 antigen, a PRRSV ORF1b antigen, a PRRSV ORF6 antigen, and a PRRSV ORF5 antigen. The fusion protein is useful for inducing antigen-specific cell-mediated and humoral responses.

Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases

A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.

Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses

Growing community of inventors

Taipei, Taiwan

Wei-I Chou